Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484116 | 1.00 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL30090969 | 1.00 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL2484112 | 1.00 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL930786 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL19777955 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL24829628 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL17453217 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL930787 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL14652919 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT | |
| SCHEMBL30378647 | 0.94 | NT5E (0.44) | NT5EALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-9045520-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140205566-A1 | CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| WO-2014082935-A1 | CYCLIC NUCLEOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| EP-2671888-A1 | 3',5'-cyclic nucleoside phosphate analogues | Gilead Pharmasset LLC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | GILEAD PHARMASSET LLC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2376515-A1 | Synthesis of purine nucleosides | Pharmasset, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075554-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | NT5E 64/4885ALDH1A1 2131/4885LMNA 1983/4885 |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | NT5E 96/4885ALDH1A1 2219/4885LMNA 1629/4885 |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | NT5E 96/4885ALDH1A1 2219/4885LMNA 1629/4885 |
| US-20140205566-A1 | CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF | NSUN2, NSUN3, DDX21 | NT5E 608/4885ALDH1A1 2311/4885LMNA 830/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | NT5E 96/4885ALDH1A1 2219/4885LMNA 1629/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | NT5E 96/4885ALDH1A1 2219/4885LMNA 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.